A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of GTX-11 in Healthy Subjects

2023-504426-19-00 Protocol GTX-PH1-001 Human pharmacology (Phase I) - First administration to humans Ended

Start 1 Oct 2024 · End 12 Oct 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol GTX-PH1-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 52
Countries 1
Sites 1

Pulmonary fibrosis

Key facts

Sponsor
Gat Therapeutics S.L.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08]
Trial duration
1 Oct 2024 → 12 Oct 2025
Decision date (initial)
2023-11-27
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Pulmonary fibrosis

VersionLevelCodeTermSystem organ class
21.1 LLT 10022619 Interstitial pulmonary fibrosis 10038738
21.0 PT 10037383 Pulmonary fibrosis 100000004855
21.1 PT 10021240 Idiopathic pulmonary fibrosis 100000004855
20.0 LLT 10016660 Fibrosis pulmonary 10038738

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Gat Therapeutics S.L.

Sponsor organisation
Gat Therapeutics S.L.
Address
Calle Baldiri Reixac 4-10, Poligono Industrial Parc Cientific De Barcelona Poligono Industrial Parc Cientific De Barcelona
City
Barcelona
Postcode
08028
Country
Spain

Scientific contact point

Organisation
Gat Therapeutics S.L.
Contact name
Administration

Public contact point

Organisation
Gat Therapeutics S.L.
Contact name
Administration

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 52 1
Rest of world 0

Investigational sites

Spain

1 site · Ended
Hospital De La Santa Creu I Sant Pau
CIM-SANT PAU, Calle De San Antonio Maria Claret 167, 08025, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2024-10-01 2025-10-12 2024-10-01 2025-09-08

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-08-25 Spain Acceptable with conditions
2023-11-20
2023-11-27
2 SUBSTANTIAL MODIFICATION SM-1 2024-07-18 Spain Acceptable
2024-08-29
2024-08-29
3 SUBSTANTIAL MODIFICATION SM-2 2024-10-07 Spain Acceptable
2025-01-03
2025-01-03